Related Experiment Video
Updated: Jul 2, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Cancer and venous thromboembolism
Paolo Prandoni1, Anna Falanga, Andrea Piccioli
1Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University of Padua, Padua, Italy. paoloprandoni@tin.it
The Lancet. Oncology
|June 1, 2005
Summary
Venous thromboembolism (VTE) is common in cancer patients due to complex interactions. Low-molecular-weight heparins are key for VTE prophylaxis and treatment in cancer, potentially improving survival.
Area of Science:
- Oncology
- Hematology
- Thrombosis Research
Background:
- Venous thromboembolism (VTE) is a frequent complication in cancer patients.
- Pathogenesis involves intricate interactions between tumor cells, the hemostatic system, and patient factors.
- Risk factors include immobility, surgery, and chemotherapy.
Purpose of the Study:
- To review the mechanisms, risk factors, and management of VTE in cancer patients.
- To highlight the role of low-molecular-weight heparins (LMWHs) in VTE prophylaxis and treatment.
- To discuss the implications of screening for occult malignancy in idiopathic VTE.
Main Methods:
- Review of existing literature on VTE in cancer.
- Analysis of pathogenetic mechanisms and risk factors.
- Evaluation of current treatment strategies, focusing on LMWHs.
Main Results:
- LMWHs are the cornerstone for VTE prophylaxis and treatment in cancer patients.
- LMWHs may offer survival benefits in select cancer patients.
- Approximately 10% of idiopathic VTE cases harbor an underlying malignancy.
Conclusions:
- Management of VTE in cancer presents unique challenges despite using standard agents.
- LMWHs are crucial for VTE management in cancer, with potential survival advantages.
- The benefit of screening for occult cancer in idiopathic VTE requires further investigation.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...